rs11705701 — IGF2BP2 IGF2BP2 Insulin Signaling Variant

IGF2BP2: When Your Pancreas Reads the Wrong mRNA

IGF2BP2 is an mRNA-binding protein with an unusual job: it acts as a post-transcriptional regulator of insulin-like growth factor 2 (IGF2), a signaling molecule critical for pancreatic development, beta cell survival, and adipose tissue metabolism. The rs11705701 variant sits about 2 kilobases upstream of the gene and subtly rewires how IGF2BP2 protein is produced — not eliminating it, but shifting which version of the protein dominates in key metabolic tissues.

The Mechanism

The IGF2BP2 gene produces two major protein isoforms: p66 (the full-length form with both RNA-binding domains intact) and p58 (a shorter isoform lacking the N-terminal RRM1 domain). These isoforms are not functionally equivalent. The p58 isoform appears to act as a post-transcriptional brake¹¹ post-transcriptional brake
A regulatory mechanism that modulates how much IGF2 protein is produced from existing mRNA transcript, helping to tune IGF2 output at the tissue level.

The A allele at rs11705701 shifts this balance: research in visceral adipose tissue²² research in visceral adipose tissue
Grishina et al. IGF2BP2 mRNA and protein levels in adipose tissue. Review of Diabetic Studies, 2013 shows that AA homozygotes have reduced p58 and elevated p66 levels. Because p58 lacks the first RNA-recognition motif, reduced p58 availability may disinhibit IGF2 mRNA translation, dysregulating the IGF2 signaling axis in adipose and islet tissue.

IGF2BP2 also functions as an m6A reader³³ m6A reader
A protein that recognizes and binds to N6-methyladenosine modifications on mRNA, a major form of epitranscriptomic regulation — it directly binds PDX1 mRNA (a master transcription factor for beta cell identity) and stimulates its translation. Pancreatic beta-cell-specific knockout studies⁴⁴ Pancreatic beta-cell-specific knockout studies
PMC8076713 — IMP2 deletion reduces compensatory beta cell proliferation by 70% and impairs glucose-stimulated insulin secretion show that loss of IGF2BP2 function dramatically impairs beta cell proliferation and insulin secretion, establishing the gene's critical role in islet homeostasis.

The Evidence

The clearest functional evidence comes from a Russian case-control study (n=2,917)⁵⁵ Russian case-control study (n=2,917)
Grishina et al. Review of Diabetic Studies, 2013 in which the A allele was associated with T2D risk (OR=1.19, p<0.001). In non-diabetic AA homozygotes, the metabolic phenotype was already visible: higher HOMA-IR (p=0.04), lower HOMA-β (p=0.012), and reduced two-hour insulin levels (p=0.016) — hallmarks of combined insulin resistance and early secretory insufficiency.

A European study using hyperglycaemic clamps⁶⁶ hyperglycaemic clamps
A gold-standard technique that holds blood glucose at a fixed elevated level while measuring insulin secretion in real time found that IGF2BP2 variants were associated with a 28% reduction in first-phase insulin secretion⁷⁷ 28% reduction in first-phase insulin secretion
Staiger et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion. Diabetologia, 2008 (n=272 NGT/IGT subjects, Netherlands and Germany), placing IGF2BP2 among the genes where T2D risk is mediated primarily through beta cell dysfunction rather than peripheral insulin resistance alone.

In Mexican Americans from the BetaGene family study (n=717), rs11705701 showed a significant interaction with adiposity⁸⁸ rs11705701 showed a significant interaction with adiposity
Knowles et al. Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity. Diabetes, 2015: each A allele was associated with ~1.5–2% lower body fat percentage. However, at higher adiposity, AA homozygotes showed the steepest decline in insulin sensitivity — meaning the A allele's effect on insulin signaling appears to be amplified by excess body fat.

Evidence is not uniformly positive. A Chinese prediabetes study (n=1,536) found an association only in females under a dominant model, and a 2024 gestational diabetes study (n=1,703) found no significant association⁹⁹ found no significant association
Zheng et al. PLoS One, 2024 for rs11705701 specifically. The variant may be a proxy marker for a nearby causal variant rather than functional itself, and population-specific LD patterns explain some of the heterogeneity across ethnicities.

Overall, the evidence supports a moderate classification: replicated signal in multiple populations and datasets, plausible mechanistic basis, but inconsistent across ethnicities and short of clinical-grade evidence.

Practical Implications

The combined phenotype — reduced beta cell reserve combined with impaired insulin sensitivity that worsens with adiposity — defines the actionable target: keep visceral fat low enough that the metabolic interaction stays in the favorable zone. This variant specifically identifies carriers who are likely to convert from insulin-sensitive to insulin-resistant more rapidly as body fat rises. Monitoring fasting insulin and two-hour post-load glucose provides earlier warning than HbA1c alone for this genotype.

The finding that p58 isoform reduction alters IGF2 pathway activity in both adipose and islet tissue suggests that interventions supporting insulin signaling efficiency (adequate chromium, zinc, and inositol as cofactors; low-glycaemic dietary pattern) are mechanistically relevant, not generic.

Interactions

The most clinically important interaction for this variant is with TCF7L2 rs7903146, the strongest single T2D GWAS signal. Both IGF2BP2 and TCF7L2 act in beta cell regulatory circuits — TCF7L2 through Wnt signaling and IGF2BP2 through IGF2/PDX1 axis. Carriers of risk alleles at both loci may carry compounded beta cell dysfunction, warranting especially proactive insulin secretory reserve monitoring.

rs11705701 is in partial but not complete linkage disequilibrium with rs4402960, the originally reported IGF2BP2 GWAS hit from the first wave of T2D genome-wide studies. In Mexican Americans, the two SNPs are in strong LD (D′≈1, r²≈0.95), but they tag different functional effects in some other populations, suggesting each contributes independently to metabolic risk.